Introduction: Chitotriosidase (CTO) is a human chitinolytic enzyme secreted by activated macrophages and polymorphonuclear neutrophils. Albeit not specific for sarcoidosis, it is increased in over 90% of patients with active disease. The aims of this study were to correlate CTO measurements with clinical assessment of sarcoidosis and to test CTO as a marker of sarcoidosis relapse. Methods: 95 patients were followed-up for 24e60 months. Serial CTO measurements were performed every 3e6 months and correlated to clinical symptoms, lung function (FVC and DLco) and chest X-ray. In 38 patients clinical outcome status (COS) at 5 years was determined. Results: Initial CTO levels were significantly higher in patients with impaired FVC/DLco (p Z 0.011 for both) but there was no correlation with standard chest X-ray stages. Patients with Loefgren's syndrome had significantly lower initial and control CTO level compared to other patients (p Z 0.011 and p Z 0.001, respectively). At follow-up there was a positive correlation of CTO and deterioration of clinical symptoms (p < 0.001), chest X-ray (p < 0.001) and FVC/DLco (p Z 0.012 and p Z 0.086, respectively). Control CTO levels were significantly lower in no disease groups versus minimal or persistent disease group as defined by COS (p Z 0.003 and p < 0.001, respectively). At relapse CTO increased for 100% or more from baseline value in 12/14 patients.
Introduction
Chitotriosidase (CTO) is a human chitinolytic enzyme secreted by activated macrophages and polymorphonuclear neutrophils. Although the role of CTO in human is still not completely elucidated, it is most likely a part of the innate immune system against chitin containing pathogens, such as fungi and some parasites [1, 2] . Its expression is upregulated by INF-g, TNF-a, LPS and GM-CSF and downregulated by IL-10 [3, 4] . In population there is a common polymorphism in the CTO gene (CHIT1) e a 24-base pair duplication which results in the production in an inactive enzyme. The approximate frequency of normal subjects (wt/wt) is 60%, heterozygotes (wt/H) 34% and homozygotes (H/H) 6% [2, 5, 6] . Heterozygotes were reported to have about 50% of CTO activity compared to wild type, whereas homozygotes have no CTO activity in any body tissue [2] .
While increased CTO is not specific for sarcoidosis [2] , it was shown to be very sensitive biomarker of active sarcoidosis [7e11] . Sensitivity is estimated to about 90% which exceeds the sensitivity of commonly used biomarker angiotensin convertase enzyme (ACE) of about 60% [12] . CTO in serum and bronchioalveolar lavage (BAL) correlated with radiological stages of sarcoidosis [7, 9, 10] . CTO in BAL was shown to correlate with quantitative HRCT score of lung volume affected by sarcoidosis [13] . There is some evidence that CTO could have prognostic value in sarcoidosis [10] . CTO was proposed as a follow-up marker both for detecting relapses of the disease and for determining the adequate patient management [10] . It was previously shown that treatment with corticosteroids reduces the activity of CTO [8, 9] . Similarly to ACE, CTO most likely reflects granulomatous burden of the disease [9, 14, 15] and this reduces after corticosteroid treatment is initiated in majority of patients [16, 17] . On the other hand, corticosteroid resistant sarcoidosis has been described. It is characterized by increased TNF-a release of alveolar macrophages [18] . TNF-a antibodies can be efficient in such cases [19e21] . There is currently no data on how CTO changes with various treatments in corticosteroid resistant sarcoidosis.
The aims of this study were to correlate CTO measurements with clinical assessment of sarcoidosis and to test CTO as a marker of sarcoidosis relapse.
Methods and subjects Subjects
The study comprised 100 consecutive patients with newly diagnosed sarcoidosis according to ATS/ERS/WASOG criteria [22] at the Department of pulmonary diseases of University medical centre Ljubljana, Slovenia. Patients were prospectively included from June 2006 to May 2011 immediately after first diagnostic work-up before introduction of any treatment. In five subjects there was no CTO activity in any sample and they were excluded from further analysis (presumed to be homozygotes for CHIT1 duplication polymorphism). The data from 95 patients is reported in the results.
All subjects gave a written consent to participate in the study which was approved by the National Ethics Committee of the Republic of Slovenia (numbers 198/05/04 and 203/02/11). The patients included were corticosteroid naïve at the time of the first sampling.
Follow-up
Study subjects had regular follow-up at our clinic every 3e6 months or more often if necessary due to symptoms. There were followed-up from 24 to 60 months (median 38.5 months). Regular examinations included: clinical assessment, chest X-ray, lung function testing and CTO sampling. CTO measurements were not available to the clinician at the time of clinical examination to avoid biasing.
Blood sampling and measurement of CTO activity
Venous blood was drawn on each occasion into a tube without anticoagulant, centrifugated and immediately stored at À20 C. The CTO activity was determined in serum using the 22 mM 4-methylumbelliferyl-b-D-N,N 0 ,N 00triacetylchitotriosiose (4 MU-chitotrioside, Sigma Chemical Co.) in citrate phosphate buffer (pH 5.2) as an enzymatical substrate. Five microlitres of serum or BAL was incubated with 100 mL of substrate for 1 h at 37 C. The reaction was stopped by adding 2.5 mL of 0.3 M glycine/NaOH buffer (pH 10.6). The reaction product, fluorescent 4methylumbelliferone, was measured using a PerkineElmer fluorimeter at excitation wave length 365 nm and emission 465 nm. The CTO activity was expressed in nmol/h/mL.
Clinical symptoms assessment
At presentation symptoms such as fever, fatigue, joint pain, cough, dyspnea or chest pain were documented. At followup visits the symptoms were graded as new, persisting or none. The patients presenting with acute clinical picture consisting of bihilar lymphadenopathy, erythema nodosum and arthalgia were considered to have Loefgren's syndrome. Screening for extrapulmonary sarcoidosis was done in all patients. The patients were not systematically evaluated for pulmonary hypertension. In cases of persistent dyspnea and persistent low diffusion for carbon monoxide echocardiography was done but there were no cases of pulmonary hypertension.
A patient was diagnosed with relapse of sarcoidosis when after a period of remission there were new symptoms compatible with sarcoidosis but not accountable to other causes, a decline in lung function (fall of 12% in FVC or 10% in DLco), worsening of chest radiograph or new extrapulmonary lesions.
Chest radiographs
Initial chest X-rays were evaluated by two chest radiologists who were unaware of the clinical diagnosis. In case of discrepancy in the evaluation, the reported result was reached by consensus. The chest X-ray readings were classified into pulmonary sarcoidosis stages: stage 0 (normal chest radiograph), stage I (bilateral hilar lymphadenopathy), stage II (bilateral hilar lymphadenopathy accompanied by parenchymal infiltration), stage III (parenchymal infiltration without hilar lymphadenopathy) and stage IV (advanced fibrosis with evidence of honeycombing, hilar retraction).
Follow-up chest radiographs were classified according to changes from initial or previous radiograph. Evaluation was done by side by side comparison of two consequent films. Radiograph was considered as improved when there was less parenchymal changes and/or decline in lymph nodes size or complete normalization of changes, unchanged when changes persisted without regression and worsened when there were more parenchymal changes and/or increase in lymph nodes size. Such classification was chosen to describe changes in lung parenchyma and lymph nodes. The extent of changes was not graded.
Lung function
Forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLco) were measured using standard technique. DLco was measured using the single-breath method. FVC and DLco were classified as normal (!80%) or as impaired (<80%).
At follow-up a change of 12% of FVC and a change of DLco of 10% were considered significant.
Therapy Study subjects received therapy for sarcoidosis in case of persisting symptoms, deterioration of radiographs or lung function, or extrapulmonary involvement of vital organs. Subjects received antifungal medication (itraconazole), corticosteroids (methylprednisolone) or combination of both, using criteria as described in previous study [23] . In brief, after a period of observation (3e6 months) the patients who were considered to have indication for treatment were given one of the described treatment options. The choice of treatment was made by informed consent e some patients preferred established therapy with corticosteroids while others agreed with experimental therapy with itraconazole or combination of both agents. The patients received therapy for 11e16 months. This study was not randomized. All patients with extrapulmonary involvement of vital organs and patients who did not respond to antifungal medication received corticosteroids.
Clinical outcome status
The patients were classified into subgroups according to classification proposed by WASOG task force [24] . The recommended period of observation for determining the clinical outcome status (COS) is 5 years. The major groups were no disease, minimal disease (less than 25% of maximal disease) and persistent disease. The patients were further divided according to the need for systemic therapy. The patients currently on therapy (or that received therapy in the last year) were additionally divided into asymptomatic, symptomatic and with functional deterioration in the last 
Results

Initial evaluation of sarcoidosis
The detailed results are shown in Table 1 . There was no correlation between CTO and gender or CTO and body mass index (BMI). There was a positive but weak correlation between age and CTO. Former smokers had significantly higher CTO compared to never smokers while the difference did not reach statistical significance against current smokers. Patients presenting with Loefgren's syndrome had significantly lower levels of CTO compared to other patients (Fig. 1A) . Extrapulmonary locations were: uvea (n Z 9), extrathoracic lymph nodes (n Z 6), skin (n Z 4), liver (n Z 3), nervous system (n Z 3), bone marrow (n Z 2), bladder (n Z 1) and kidneys (n Z 1). Two patients had more than one organ affected (uvea þ extrathoracic lymph nodes and uvea þ liver). There was no significant difference in CTO levels between patients with or without extrapulmonary sarcoidosis. Patients with impaired FVC or DLco had significantly higher CTO levels compared to patients with normal FVC or DLco. In this group of study subjects there was no correlation between chest X-ray staging of pulmonary sarcoidosis and CTO levels. (Table 2) showed very good correlation of CTO and changes in clinical symptoms and chest X-ray. CTO was particularly increased when new clinical symptoms or progression of chest X-ray changes were noted. Significantly higher CTO levels were measured when there was decline in FVC compared to increase or stable values of FVC but this was only borderline significant for DLco. There was no difference between CTO in stable lung function or at increase.
Follow-up and serial CTO measurements
Figure 1
A e Initial and control CTO values (3e6 months after therapy discontinuation or observational period of 12e15 months) in patients with Loefgren's syndrome compared to other patients. *Significant difference between group with Loefgren's syndrome and other patients in initial CTO (p Z 0.011). #Significant difference between groups in control CTO (p Z 0.001). B e Initial and control CTO values in COS groups. *No significant difference in initial CTO between groups with no disease and minimal disease (p Z 0.106) or between groups with no disease and persistent disease (p Z 0.074). #Significant difference in control CTO between groups with no disease and minimal disease (p Z 0.003) and between groups with no disease and persistent disease (p < 0.001).
Clinical outcome status and CTO measurements
In total, COS at 5 years could be determined for 38 (40%) patients. Eleven patients that could complete 5 years were lost to follow-up (22.4% of potential 5-year follow-up group). Due to small number of patients the analysis was done only on major COS groups: no disease (COS 1 and 2), minimal disease (COS 3 and 4) and persistent disease (COS 5e9). The results are shown in Table 3 and Fig. 1B . The initial CTO values did not correlate with COS but there was a trend towards higher CTO values in patients with minimal or persistent disease (p Z 0.106 for no disease versus minimal disease and p Z 0.074 for no disease versus persistent disease). The control CTO values were significantly lower in the patients with no disease compared to patients with minimal (p Z 0.003) or persistent disease (p < 0.001). The difference was significant even if patients with Loefgren's syndrome were excluded from the analysis (5 completed the required follow-up, 1 had persistent disease).
Relapse of sarcoidosis
Subjects who had relapse of sarcoidosis in the observational period (median time from diagnosis to relapse was 28 months) had significantly higher CTO at presentation compared to subjects who did not have relapse (Table 4 ). CTO at diagnosis was however neither sensitive nor specific for predicting future relapses, as receiver operating characteristic (ROC curve) yields area under the curve of only 0.680. The difference disappeared 3e6 months after therapy was discontinued (or after 12e15 months of observation for patients who did not receive any therapy). At the time of relapse there was a distinct peaking of CTO (Fig. 2) . In 12 of 16 patients with relapse the increase of CTO was over 100% of control value (range 108e532%), in 1 patient the increase was 48% and in 1 patient 5%. In no patient CTO at relapse was below the control value. In 2 patients we could not obtain control CTO values due to early relapse after termination of therapy.
Discussion
In this study CTO was shown to correlate with the clinical presentation of sarcoidosis, lung function (FVC and DLco) and age of patients. There was lack of correlation with chest X-ray staging of pulmonary sarcoidosis. A drawback of this study is that it included mostly patients with sarcoidosis stages I and II (88.5%) and only small number of patients with other stages. A correlation of all radiographical stages and serum CTO levels was previously reported [7] , but further studies only partially confirmed this. In two studies CTO was higher in stages III and IV as compared to 0 and I [10, 25] and in one there was borderline positive correlation between stage I and stages IIeIV [9] . This is likely due to other factors that affect CTO level, such as the extent of lung infiltration or large extrapulmonary granulomatous Data are given as median (IQR). *No significant difference in initial CTO between groups with no disease and minimal disease (p Z 0.106) or between groups with no disease and persistent disease (p Z 0.074). **Significant difference in initial CTO between groups with no disease and minimal disease (p Z 0.003) and between groups with no disease and persistent disease (p < 0.001).
infiltration. Moreover, chest X-ray stages do not reflect activity of the disease but merely describe the presence of lymphadenopathy and lung infiltration at one time point [26] . To obtain information about activity of inflammation serial radiographs are necessary which was done in the follow-up part of this study. On the other hand, it was observed that patients with FVC or DLco below normal values had significantly higher CTO values. Higher CTO values most likely reflect higher granulomatous infiltration which is the cause of decline in lung function. Serum soluble interleukin-2 receptor (sIL-2R) is also considered a biomarker of active sarcoidosis and it was reported to positively correlate with CTO [8, 25] . It is considered a marker of CD4þ lymphocyte activation [27] (as opposed to CTO which derives from macrophages). Contrary to CTO, sIL-2R was higher in lower radiographic stages of sarcoidosis [25, 27] and did not correlate with impaired lung function [27] . High sIL-2R is possibly a predictor of good clinical outcome of sarcoidosis [27] although increased sIL-2R values were observed in progressive sarcoidosis also [25] . This suggests that CTO and sIL-2R might be used as complementary biomarkers (in example, low sIL-2R and high CTO could indicate complicated disease and vice versa) but further research is needed to explore this hypothesis. The patients with Loefgren's syndrome had significantly lower CTO compared to other patients. This group is known to have the best outcome, experiencing spontaneous remission in over 80% [22] and this is in line with hypothesis that low CTO indicates good clinical outcome [10] . Interestingly, in a study on sIL-2R in sarcoidosis, patients with pulmonary sarcoidosis and erythema nodosum (6/8 patients had classic Loefgren's syndrome) had higher sIL-2R values compared to patients with pulmonary sarcoidosis only [27] . Bargagli et al. reported correlation between CTO and clinical outcome status (COS) [10] . In particular, patients with persistent disease (COS 5, COS 6, COS 8 and COS 9) had higher CTO values compared to COS 1 group. The results from this study shows similar pattern, CTO being lower in no disease group as compared to minimal or persistent disease groups. Although the difference in initial CTO values did not reach statistical significance the authors believe there is a true association that would be reach statistical significance in larger number of patients. Control CTO values were significantly lower in no disease group compared to other two groups. This shows that persistently high CTO values after therapy or observational period might be even more predictive for chronic disease.
Positive correlation between age and CTO has been previously described in healthy subjects [28, 29] so this finding in this study group could reflect normal aging process. On the other hand, it has been reported that older patients with sarcoidosis have worse prognosis and worse clinical outcome status score [24] .
The observation that CTO was significantly higher in former smokers compared to never smokers was unexpected. It has been reported that smoking increases CTO activity in chronic obstructive pulmonary disease [30, 31] but this does not explain the observation. While it could be just a chance occurrence, it was reported that smoking cessation increases metabolic activity of macrophages [32] . The influence on airway inflammation differs in patients with chronic obstructive disease compared to asymptomatic smokers [33] . In one study of wound healing smoking cessation restored inflammatory but not proliferative processes [34] . If this somehow applies to sarcoid macrophages remains to be elucidated.
The limitation of the reported data is that CTO values are not corrected for genotype (common inactivating 24 bp duplication polymorphism of CHIT1 gene). In one study it was shown that the distribution of CHIT1 duplication polymorphism in Slovenian sarcoidosis patients does not differ from general population [5] . Currently there is no information on whether CHIT1 polymorphism has any effect on sarcoidosis phenotype as no previous studies on sarcoidosis and CTO reported genetic data. Our limited unpublished data suggests that there are no differences in sarcoidosis phenotypes between wt/wt and wt/H subjects (and no clustering), but further research is needed to confirm this. In the follow up part of the study serial measurements of CTO showed a good correlation with changes in chest X-ray and clinical symptoms and less strong correlation with changes in lung function. A drawback of this data is that changes in chest X-ray were not quantified using a scoring system. Nevertheless, side by side evaluation of chest X-ray is considered a valid and accurate method [35, 36] . The results in this study might be biased to some extent because time sequence of chest X-rays was known. In previous longitudinal studies similar relationships were found for ACE [37, 38] . The major advantage of CTO in comparison to ACE is its greater sensitivity [7e10]. The limited data on sIL-2R suggests association between decline of sIL-2R and improvement in chest X-ray [27] . CTO could thus be used to reduce the number of needed investigations for monitoring disease progression as this was unlikely if there was no increase in CTO value. In future studies it would be of interest to compare CTO activity and 18F-FDG PET/CT which is very sensitive imaging method for detection of the extension of inflammation in granulomatous sites and can assess activity of inflammation [39e41].
Finally, CTO was also evaluated as a marker of relapse of the disease. The major shortcoming of this data is that patients were observed for uneven periods of time (24e60 months). Nevertheless, high initial CTO value appeared to be weak predictor of future relapse. At relapse an increase from control values of over 100% was detected in 12/14 patients.
In conclusion, CTO was shown to correlate with certain sarcoidosis phenotypes, such as Loefgren's syndrome and COS. Additionally, it was shown that serial measurements of CTO positively correlate with clinical symptoms, chest radiographs and lung function. This confirms previous observations that CTO is a good marker of sarcoidosis activity. Taking high sensitivity of CTO for sarcoidosis in to account, serial CTO measurements could be used to reduce the number of other diagnostics procedures (such as chest radiographs) or to support decision for additional examinations (such as PET-CT).
